-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 7, 2021, Mirati Therapeutics announced a clinical cooperation agreement with Sanofi
Adagrasib is a highly specific and potent oral KRAS G12C inhibitor, which has been optimized for long-lasting target inhibition
SAR442720 is a potent oral SHP inhibitor
▲SHP2 regulates the RAS signaling pathway (picture source: Revolution Medicines official website)
Because KRAS G12C inhibition and SHP2 inhibition have complementary mechanisms of action, they exhibit cumulative anti-tumor activity in preclinical models
Reference materials:
Reference materials:[1] Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer.
[1] Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer.
Retrieved October 8, 2021, from https://ir.
mirati.
com/press- releases/press-release-details/2021/Mirati-Therapeutics-to-Collaborate-with-Sanofi-on-Phase-12-Study-Evaluating-Combination-of-adagrasib-with-a-SHP2-Inhibitor-in-KRAS- G12C-mutated-Lung-Cancer/default.
aspx